Consultation record
Submissions not accepted — page 3
The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.
Submissions
147 documents · page 3 of 5
Table 1. Submissions with this disposition, on this page.
| Reference | Consultation | Respondent | Point raised |
|---|---|---|---|
| DRAFT-AMYCRETIN-MO/006 | Draft monograph: amycretin | Dr Jerome Petrossian | The document set should be published in translation |
| DRAFT-5-AMINO-1MQ-/006 | Draft monograph: 5-amino-1MQ | Dr Lorcan Zaleski-Mbeki industry | The document should not describe uses outside the approved indication |
| DRAFT-AOD-9604-MON/002 | Draft monograph: AOD-9604 | Dr Jacinta Grünbaum-Sowande | The document set should be published in translation |
| DRAFT-AOD-9604-MON/017 | Draft monograph: AOD-9604 | Ignatius Erlingsson | The monograph should state what the compound costs |
| DRAFT-CAGRISEMA-MO/004 | Draft monograph: CagriSema (cagrilintide with semaglutide) | Dr Liesbeth Achterberg | The monograph should state what the compound costs |
| DRAFT-ECNOGLUTIDE-/001 | Draft monograph: Ecnoglutide | Dr Jacinta Steenkamp-Ferreira | The monograph should state what the compound costs |
| DRAFT-EPITHALON-MO/001 | Draft monograph: Epithalon | Professor Ekaterina Voskresenskaya-Hill industry | The document should not describe uses outside the approved indication |
| DRAFT-EXENATIDE-MO/003 | Draft monograph: Exenatide | Xiomara Fairweather-Duru | The monograph should state what the compound costs |
| DRAFT-EXENATIDE-MO/005 | Draft monograph: Exenatide | Dr Leonhard Quenneville | The document set should be published in translation |
| DRAFT-GHK-CU-MONOG/007 | Draft monograph: GHK-Cu | Dr Jacinta Steenkamp-Ferreira | The monograph should state what the compound costs |
| DRAFT-GHRP-6-MONOG/011 | Draft monograph: GHRP-6 | Kolawole Jankowiak-Osei | The monograph should state what the compound costs |
| DRAFT-GHRP-6-MONOG/003 | Draft monograph: GHRP-6 | Quentin Gwynne-Sarpong | The document should state what a reader ought to do |
| DRAFT-GLUTATHIONE-/009 | Draft monograph: Glutathione | Dr Ndidi Ravensworth-Ilunga industry | The document should not describe uses outside the approved indication |
| DRAFT-IPAMORELIN-M/006 | Draft monograph: Ipamorelin | Dr Abimbola Sotomayor-Ekwueme | The document set should be published in translation |
| DRAFT-KPV-MONOGRAP/005 | Draft monograph: KPV | Dr Delphine Ravensworth industry | The document should not describe uses outside the approved indication |
| DRAFT-LARAZOTIDE-M/005 | Draft monograph: Larazotide acetate | Dr Rurik Haverkamp-Diallo | The monograph should state what the compound costs |
| DRAFT-LIXISENATIDE/010 | Draft monograph: Lixisenatide | Dr Rosalind Grünbaum-Sowande industry | The document should not describe uses outside the approved indication |
| DRAFT-MARIDEBART-C/008 | Draft monograph: Maridebart cafraglutide | Dr Emiliana Ollerenshaw | The monograph should state what the compound costs |
| DRAFT-MAZDUTIDE-MO/004 | Draft monograph: Mazdutide | Dr Lorcan Trelawney | The document should state what a reader ought to do |
| DRAFT-MELANOTAN-II/003 | Draft monograph: Melanotan-II | Dr Ilona Mbatha-Fredriksen | The document should state what a reader ought to do |
| DRAFT-MOTS-C-MONOG/005 | Draft monograph: MOTS-c | Dr Odalys Thorsby-Nakamura | The monograph should state what the compound costs |
| DRAFT-NAD-PLUS-MON/001 | Draft monograph: NAD+ (nicotinamide adenine dinucleotide) | Dr Vasilisa Immelmann industry | The document should not describe uses outside the approved indication |
| DRAFT-NAD-PLUS-MON/002 | Draft monograph: NAD+ (nicotinamide adenine dinucleotide) | Dr Ludmila Castellanos-Reid | The monograph should state what the compound costs |
| DRAFT-ORAL-SEMAGLU/008 | Draft monograph: Semaglutide, oral | Dr Stellan Cholmondeley-Ade | The document should state what a reader ought to do |
| DRAFT-PRAMLINTIDE-/012 | Draft monograph: Pramlintide | Dr Lorcan Zaleski-Mbeki | The document set should be published in translation |
| DRAFT-PRAMLINTIDE-/004 | Draft monograph: Pramlintide | Dr Ilona Mbatha-Fredriksen | The document should state what a reader ought to do |
| DRAFT-PT-141-MONOG/012 | Draft monograph: PT-141 (bremelanotide) | Dr Georgiana Mountstephen | The document set should be published in translation |
| DRAFT-SELANK-MONOG/008 | Draft monograph: Selank | Dr Yehudit Yorkstone | The monograph should state what the compound costs |
| DRAFT-SS-31-MONOGR/002 | Draft monograph: SS-31 (elamipretide) | Dr Eamon Sandringham-Adu | The document should state what a reader ought to do |
| DRAFT-SS-31-MONOGR/012 | Draft monograph: SS-31 (elamipretide) | Dr Xenia Uttridge | The monograph should state what the compound costs |
page 3 of 5